Navigation Links
Gladstone's Shinya Yamanaka wins Kyoto prize
Date:6/18/2010

SAN FRANCISCO, CAJune 18, 2010 Shinya Yamanaka, MD, PhD, of the Gladstone Institute of Cardiovascular Disease (GICD) and Kyoto University, has won the 2010 Kyoto Prize for Advanced Technology. Yamanaka, who is the L.K.Whittier Investigator in Stem Cell Biology at Gladstone, and professor of anatomy at UCSF, was cited for his discovery of a method of reprogramming adult skin cells to become embryonic-like stem cells. The discovery has opened up the field of stem cell research and dramatically changed the field of cell biology.

The Kyoto Prize is an international award honoring those who have contributed significantly to humankind's scientific, cultural, and spiritual development. The prize is presented annually in three categories: Advanced Technology, Basic Sciences, and Arts and Philosophy. Consisting of academic honors, a commemorative gold medal and a cash gift of 50 million yen (approximately $500,000), it is Japan's highest private award for global achievement.

While other scientists continued to experiment with a traditional approach to learn how embryonic stem cells differentiate to become different kind of cells, Dr. Yamanaka and his team took what was considered a contrarian approach to learn how differentiated adult cells might be reprogrammed back to their embryonic or "pluripotent" state. Yamanaka and his colleagues found that by introducing four genetic factors, skin cells from an adult would transform into cells that behaved just like embryonic stem (ES) cells, and he coined the term "induced pluripotent stem cells" or iPS cells. The simplicity of Yamanaka's technology was initially met with skepticism, but Yamanaka made his data and the DNA of his work publicly available to enable any scientist to work with these new cells, and within months scientists across the world had reproduced and adopted this new approach to generating and studying stem cells.

"Dr. Yamanaka fundamentally changed the way we think about the biology of stem cells and opened new possibilities for the practical applications of that knowledge," said R.Sanders Williams, MD, PhD, Gladstone president. "That adult cells could be reprogrammed and assigned different properties is one of the most significant discoveries of this decade."

Since Yamanaka's discovery, he and other scientists have learned more efficient ways to make iPS cells and have used them to create other types of cells including neurons, heart cells etc. Many have made iPS cells from patients with disease and hope to use these human cells to model the disease, so that new drug therapies could be discovered to alleviate human suffering.

The Kyoto Prize is given by the Inamori Foundation, which was established in 1984 by Dr. Kazuo Inamori, founder and chairman emeritus of Kyocera and KDDI Corporation. The Kyoto Prize was established, in line with Dr. Inamori's belief that a human being has no higher calling than to strive for the greater good of society, and that the future of humanity can be assured only when there is a balance between our scientific progress and our spiritual depth. An emblematic feature of the Kyoto Prize is that it is presented not only in recognition of outstanding achievements, but also in honor of the excellent personal characteristics that have shaped those achievements.


'/>"/>

Contact: Valerie Tucker
vtucker@gladstone.ucsf.edu
41-577-342-019
Gladstone Institutes
Source:Eurekalert

Related biology news :

1. Gladstones Shinya Yamanaka wins prestigious Shaw Prize
2. Gladstones Shinya Yamanaka wins Lasker Award
3. Yamanaka eliminates viral vector in stem cell reprogramming
4. Sakayu Shimizu of Kyoto University recipient of 2009 Enzyme Engineering Award
5. ETH Zurich professor Ari Helenius awarded Benoist Prize
6. Columbia to award 2007 Horwitz Prize to three generations of teacher-student scientists
7. Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine
8. Professor Sir Martin Evans wins Nobel Prize for Medicine
9. Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer
10. Nobel Peace Prize 2007 to intergovernmental panel on climate change
11. NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology: